Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS

By PBR Staff Writer

Rhythm Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).